Drug intelligence / Profile preview

JMEY-FS81

Development stage: Preclinical
Lead developer: Jianmin Pharmaceutical Group

Overview

JMEY-FS81 is an investigational drug candidate currently in preclinical development by Jianming Pharmaceutical Group (also known as Wuhan Jianming Pharmaceutical). It is being developed for the treatment of edema. As of the current pipeline disclosures, the specific molecular target, mechanism of action, and chemical modality (e.g., small molecule or biologic) have not been publicly identified. The program is situated in the CMC and preclinical testing phase of the company's research and development pipeline.

Beyond the preview

Go deeper on JMEY-FS81.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-FS81.

Explore the full profile